K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 045 JPY 0.12% Market Closed
Market Cap: ¥153.2B

Gross Margin

56.1%
Current
Declining
by 0.6%
vs 3-y average of 56.7%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
56.1%
=
Gross Profit
¥46B
/
Revenue
¥82B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
56.1%
=
Gross Profit
¥46B
/
Revenue
¥82B

Peer Comparison

Country Company Market Cap Gross
Margin
JP
Kaken Pharmaceutical Co Ltd
TSE:4521
153.2B JPY
Loading...
US
Eli Lilly and Co
NYSE:LLY
969.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.3B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Higher than 83% of companies in Japan
Percentile
83nd
Based on 6 625 companies
83nd percentile
56.1%
Low
-179.8% — 21.8%
Typical Range
21.8% — 42.3%
High
42.3% — 18 197.9%
Distribution Statistics
Japan
Min -179.8%
30th Percentile 21.8%
Median 30.6%
70th Percentile 42.3%
Max 18 197.9%

Kaken Pharmaceutical Co Ltd
Glance View

Market Cap
153.2B JPY
Industry
Pharmaceuticals

Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.

Intrinsic Value
1 829.34 JPY
Overvaluation 55%
Intrinsic Value
Price
K
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
56.1%
=
Gross Profit
¥46B
/
Revenue
¥82B
What is Kaken Pharmaceutical Co Ltd's current Gross Margin?

The current Gross Margin for Kaken Pharmaceutical Co Ltd is 56.1%, which is below its 3-year median of 56.7%.

How has Gross Margin changed over time?

Over the last 3 years, Kaken Pharmaceutical Co Ltd’s Gross Margin has increased from 54.4% to 56.1%. During this period, it reached a low of 53.4% on Jun 30, 2024 and a high of 62.2% on Mar 31, 2025.

Back to Top